Efficacy and Safety of Tauroursodeoxycholic Acid (Taurolite) for Dissolution of Cholesterol Gallstones:Multicenter Double-Blind Randomized-Controlled Trial

傅贤波,林三仁,范竹萍,邱德凯
DOI: https://doi.org/10.3969/j.issn.1009-6604.2007.12.019
2007-01-01
Abstract:Objective To evaluate the safety and therapeutic efficacy of tauroursodeoxycholic acid(Taurolite) for dissolution of cholesterol stones in gallbladder.Methods From October 2003 to December 2004,a multicenter double-blind randomized-controlled trial of Taurolite(containing tauroursodeoxycholic acid 250 mg) for dissolution of cholesterol gallstones in gallbladder was carried out.All the subjects were the asymptomatic patients or patients with mild epigastric flatus,whose diagnosis of cholecystic radiolucent stones in the functioning gallbladder was confirmed by B-ultrasonography and oral cholecystography(OCG).The maximum diameter of the stones was less than 2 cm.Each patient was informed as to the aims of the experiment and gave his consent(underwrited consent).All the subjects were randomly divided into both experimental(E) and control(C) groups.One capsule of Taurolite was given to the E group,while placebo(in the same capsule without tauroursodeoxycholic acid) was given to the C group.B-ultrasonography,OCG,blood routine(count of white blood cells,red blood cells,blood platelet,and haemoglobin),hepatic function(alanine aminotransferase,ALT;aspartate aminotransferase,AST;alkaline phosphatase,ALP;total bilirubin,TBil;and albumin,ALB;) and kidney function(urea nitrogen,BUN and creatine,Cr;) tests were carried out before and every two months after the treatment to evaluate the side-effect and therapeutic efficacy of Taurolite.The blind answer was revealed at the fourth month.The experiment was stopped in the C group at the fourth month,but was continued for another two months(total experimental time was 6 months) in the E group in order to have enough time for stone-dissolution.Therapeutic efficacy was evaluated by examining number and size of the gallstones by B-ultrasonography and OCG.Criteria of therapeutic efficacy were as follows: complete dissolution(CD): disappearance of gallstones;greater part dissolution(GPD): more than 50% decrease(number or size);partial dissolution(PD): less than 50% decrease(number or size);No change(NC): unchanged or increased number or size of the stones.CD+GPD was considered as prominent efficacy,CD+GPD+PD was considered as effective.Results A total of 123 patients,including 64 patients in E group and 59 patients in C group,were enrolled into this trial.During the experiment,11 cases(2 in E group and 9 in C group) withdrew from the trial.The seceding ratio was 8.9%.112 cases(62 in E group and 50 in C group) completed the experiment.There was no statistical difference between E and C groups in the distribution of sex,age,and number and size of stones(t test or χ2 test,P>0.05).Both the groups were comparable.(1) Prominent rate of therapeutic efficacy(CD+GPD) at the fourth month for Taurolite was 27.4%(17/62),and the effective rate(CD+GPD+PD) was 56.5%(35/62).Prominent rate at the sixth month for Taurolite was 41.9%(26/62),and the effective rate was 67.7%(42/62).In the C group,4 cases(8.0%) showed dissolution response and 46 had NC.A significant difference was seen between the two groups(χ2=28.678,P=0.000).(2) No severe adverse event occurred.Four patients had adverse events [3(4.8%) in E group and 1(2.0%) in C group].The symptom of 2 cases might be related to the drug,the rate of drug-related adverse events was 1.8%(2/112).(3) No significant difference existed between pre-treatment and the 2nd and 4th month after the treatment in blood routine,and hepatic and kidney function tests(ALT,AST,ALP,TBil,ALB,Cr,BUN) in E group(P>0.05).The changes in blood routine,and hepatic and kidney functions were not related to the amount of Taurolite taken.(4) Compared with the control group,no significant difference existed in blood routine,hepatic and kidney function test between pre-treatment and the 2nd,4th month after treatment in the E group(P>0.05).The changes in blood routine,and hepatic and kidney functions were not related to Taurolite.Conclusion Taurolite is a safe and effective drug for the treatment of cholesterol stone in gallbladder.
What problem does this paper attempt to address?